Tuesday, October 25, 2016

Spotlight Innovation Enters into Sponsored Research Agreement with Florida State University to Support Prof. Hengli Tang in the Development of Treatments for Zika Virus Infection

Source:  Spotlight Innovation, Inc.

Spotlight Innovation Inc. (OTCQB: STLT) has entered into a Sponsored Research Agreement with Florida State University (FSU) to support research directed by FSU Prof. Hengli Tang aimed at developing safe and effective drugs to treat patients infected with Zika virus (ZIKV).

Prof. Tang is an accomplished virologist whose research has been published in prominent academic journals including Cell and Journal of Virology. In March 2016, Prof. Tang co-authored a study1 published in Cell Stem Cell that demonstrated for the first time the ability of ZIKV to target human embryonic cortical neural progenitor cells. After infecting these crucial brain development cells, the virus replicates and interferes with cell growth, function and viability. ZIKV infection in pregnant women can cause neurological birth defects, including microcephaly, a condition in which a child is born with an abnormally small head as a result of incomplete brain development.

Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development, commented, "Prof. Tang is a true pioneer in the scientific community's efforts to combat Zika virus. We are thrilled that he has chosen to collaborate with us to develop novel therapies for Zika virus infection."

About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Spotlight Innovation Launches Development of STL-182 to Treat Spinal Muscular Atrophy

Source:  Spotlight Innovation, Inc.

Spotlight Innovation Inc. (OTCQB: STLT) today announced that it has obtained an exclusive, worldwide license from Indiana University Research and Technology Corp. to commercialize STL-182, an orally-available small molecule that may have therapeutic potential for treating Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is a leading genetic cause of death in infants and toddlers. Synthesis and early preclinical testing of STL-182 was accomplished through a research collaboration between Professors Elliot Androphy of Indiana University School of Medicine and Kevin Hodgetts, director of the Laboratory for Drug Discovery in Neurodegeneration at Brigham and Women's Hospital. Their work was supported in part by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Child Health and Human Development (NICHD).

Spinal Muscular Atrophy affects between 1 in 6,000 and 1 in 10,000 newborns. Approximately 1 in 40 to 1 in 50 adults have only a single intact spinal motor neuron 1 (SMN1) gene, which encodes a protein (SMN) required for proper neuromuscular function. An infant who inherits no intact SMN1 gene from either parent may develop SMA and lose the ability to sit, stand, walk, swallow, and/or breathe. In about 60% of cases, patients with SMA die by age two.

Even in SMA patients, low levels of functional SMN protein are produced by an SMN1-related gene called SMN2. One therapeutic strategy to treat SMA is to increase levels of functional SMN protein encoded by SMN2. In mouse models of SMA, STL-182 may restore neuromuscular function by stabilizing endogenous SMN protein.

About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.



Spotlight Innovation's Newly Established Subsidiary Caretta Therapeutics Enters into Exclusive Licensing Agreement to Develop and Commercialize Analgesic Products

Source:  Spotlight Innovation, Inc.

Spotlight Innovation Inc. (OTCQB: STLT) today announced that it has established subsidiary Caretta Therapeutics, and that the subsidiary has entered into a licensing agreement with Dr. Paul Reid for rights to develop and commercialize products derived from snake venom that may provide analgesic relief from moderate to severe chronic pain. Under the terms of the agreement, Dr. Reid has agreed to grant an exclusive, worldwide license to Caretta Therapeutics to develop, manufacture and sell the products.

Caretta Therapeutics intends to begin manufacturing its first products by late 2016 and to begin commercial distribution of over-the-counter formulations beginning in 2017.
The National Institutes of Health's National Center for Complementary and Integrative Health, utilizing data from the 2012 National Health Interview Survey, estimates that nearly 50 million American adults have significant chronic pain or severe pain.

About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Spotlight Innovation Research Collaborator Prof. Hengli Tang Publishes Landmark Study in Nature Medicine

Source:  Spotlight Innovation, Inc.

Drug Repurposing Screen Identifies Lead Compounds for Anti-Zika Virus Drug Development

Spotlight Innovation Inc. (OTCQB: STLT) announced today that Prof. Hengli Tang has co-authored a study1, published in Nature Medicine on August 29, 2016, reporting two classes of compounds: one that protects Zika virus-infected neural cells from programmed cell death ("apoptosis") and another that directly inhibits Zika virus replication. According to the study, when used in combination, compounds from the two classes enhanced the neuroprotective effect.

Since the resurgence of Zika over a year ago, efforts to combat the virus have focused largely on preventing infection through vaccine development, mosquito control measures and public health education. The availability of anti-Zika therapeutics could provide physicians with tools to treat patients who have already been infected. Funding provided by Spotlight Innovation under a Sponsored Research Agreement with Florida State University will enable Prof. Tang and his collaborators to expand on their discoveries and to accelerate the development of safe and effective drugs to treat patients infected with Zika.

Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development, commented, "Prof. Tang's important work reinforces our long-standing conviction that he and his collaborators will significantly advance the field of anti-Zika virus drug development."
In a recent publication2, Prof. Tang and his collaborators demonstrated that Zika virus can infect and replicate within human embryonic cortical neural progenitor cells. Zika infection in pregnant women can cause neurological birth defects, including microcephaly, a condition in which a child is born with an abnormally small head as a result of incomplete brain development.

About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

1 Miao X, Lee EM, Wen Z, Cheng Y, Huang W-K, Qian X, TCW J, Kouznetsova J, Ogden SC, Hammack C, Nguyen HN, Itkin M, Hanna C, Shinn P, Allen C, Michael SG, Simeonov A, Huang W, Christian KM, Goate A, Brennand K, Huang R, Menghang X, Ming G-L, Zheng W, Song H, Tang H. Identification of Small Molecule Inhibitors of Zika Virus Infection and Induced Neural Cell Death Via a Drug Repurposing Screen. Nature Med. 2016 Aug 29. 
http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.4184.html

2 Tang H, Hammack C, Ogden SC, Wen Z, Qian X, Li Y, Yao B, Shin J, Zhang F, Lee EM, Christian KM, Didier RA, Jin P, Song H, Ming GL.  Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth. Cell Stem Cell. 2016 Mar 3. pii: S1934-5909(16)00106-5. doi: 10.1016/j.stem.2016.02.016. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/26952870


Spotlight Innovation Announces Debt Restructuring Through Conversion of $850,000 in Convertible Promissory Notes

Source:  Spotlight Innovation, Inc.

Spotlight Innovation Inc. (OTCQB: STLT) announced today that the holders of a series of convertible promissory notes issued between December 2015 and March 2016, totaling $850,000, have agreed to convert the promissory notes into shares of Common Stock.

"This conversion is a positive step toward simplifying our balance sheet," said Mr. Cristopher Grunewald, Spotlight Innovation's President and Chief Executive Officer. "Debt restructuring allows us to accelerate development of our product candidates, creating value for both current and future shareholders. Moving forward, we will continue to look for debt restructuring opportunities that further our development goals."

About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Thursday, October 20, 2016

Medovex Corporation Begins Commercial Production of DenerveX™ Pro-40 Generator in Preparation for EU Launch

Source:  Medovex Corp.

Medovex Corporation Begins Commercial Production of DenerveX™ Pro-40 Generator in Preparation for EU Launch 

Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that it and its design and manufacturing partner Bovie Medical have commenced commercial production of the Company's DenerveX™ Pro-40 Power Generator as one more step towards the launch in the EU. Bovie Medical is a Florida based world leader in the development and manufacture of electrosurgical products.

"Bovie is a highly respected leader in this field," said Jarrett Gorlin, Chief Executive Officer of Medovex Corporation. "We are very pleased to nearing the completion of the design and testing stage, now moving to commercial production. Working with Bovie Medical has ensured that the power source to the DenerveX Device, focused on treatment of patients with Facet Joint Pain, will be safely and effectively matched with the device itself." The DenerveX Power generator Pro-40 was specifically designed and manufactured as a dedicated power generator for the Company's DenerveX Device.

According to Patrick Kullmann, President and COO, "The DenerveX Pro-40 generator will offer the optimal power source to the single use DenerveX device without relying on other less reliably matched power sources in the market today. The DenerveX system consists of the DenerveX Pro-40 generator and the DenerveX device. The combined system results in an exclusively matched system that will serve our customers and their patients well in the areas of quality of therapy delivery and safety. The DenerveX Pro-40 will provide both RF energy and motor power to the DenerveX device for the treatment of Facet Joint Syndrome, a very common and problematic source of back pain."

The Company's patented DenerveX System, currently in the final development stages and not yet commercially available, is designed to provide longer lasting relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.

The DenerveX System consists of the DenerveX device kit, a single use device, and the reusable DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined procedure is expected to provide a longer lasting solution and potential savings to the health care system.

DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

 


Medovex Corp. Completes Financing Led by Sorrento Therapeutics, Inc.

Source:  Medovex Corp.

Medovex Corp. Completes Financing Led by Sorrento Therapeutics, Inc.

Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced the successful completion of a $1,150,000 financing transaction led by an investment from Sorrento Therapeutics, Inc. (NASDAQ: SRNE).

On August 5, 2016, MedoveX Corporation entered into a unit purchase agreement with selected accredited investors. Pursuant to the terms of the agreement, the Company sold 4.6 units for gross proceeds of $1,150,000. Each unit had a purchase price of $250,000 and consists of 208,333 shares of the Company's common stock, and a warrant to purchase 104,167 shares of common stock. Each warrant has an initial exercise price of $1.52 per share, subject to adjustment, and is initially exercisable six months following the date of issuance for a period of five years from the date of issuance.

Sorrento Therapeutics, Inc. acted as the lead investor contributing $750,000.

Jarrett Gorlin, Medovex Corporation Chief Executive Officer, stated, "We are clearly pleased to have closed this financing led by Sorrento Therapeutics. We believe their sizeable investment is indicative of a shared optimism regarding the potential for the development and future commercialization of the DenerveX™ System. We continue to work aggressively towards a future CE mark process and successful launch in the European Union and other countries that accept the CE mark globally."

Gorlin continued, "Recent test results found that the DenerveX kit and generator successfully worked together in an excellent manner, as designed and developed at this stage of development. The successful tests pave the way towards the completion of the final set of testing and verification. The system used in this laboratory testing consisted of the latest pre-production model of the system that is the identical model to the device for human use. It represents a continued confirmation of the future utility of the DenerveX System in treating patients with Facet Joint Syndrome."

Additional details of the financing may be found in the Form 8K filed with the Securities and Exchange Commission on August 8, 2016.

The Company's patented DenerveX System, currently in the final development stages and not yet commercially available, is designed to provide longer lasting relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.

The DenerveX System consists of the DenerveX device kit, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined procedure is expected to provide a longer lasting solution and potential savings to the health care system.

DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Medovex Corporation Reports Successful Demonstration of Expanding EMEA Business at EuroSpine 2016, Berlin, Germany

Source:  Medovex Corp.

Medovex Corporation Reports Successful Demonstration of Expanding EMEA Business at EuroSpine 2016, Berlin, Germany

Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that the Company successfully exhibited its' DenerveX™ System during EuroSpine 2016 Tradeshow last week in Berlin, Germany.

As part of the product exhibition, Medovex highlighted its innovative DenerveX™ System, a minimally invasive surgical (MIS) procedure pioneered by Medovex that was built around the denervation of the posterior capsulectomy of the Facet Joint using our patented Rotablation™ technology which is "A significant paradigm shift in the treatment of Facet Joint pain."

Patrick Kullmann, President and COO for Medovex, stated, "We consider EuroSpine 2016 in Berlin our 'pre-launch' meeting leading up to what is expected to be an eventual formal CE Marking. In particular, we were very pleased to see visiting surgeons and distributors from more than 25 countries, and from all continents, at our booth, along with existing and new potential distributors visiting with us."

Kullmann continued, "Importantly, we conducted meetings and demonstrations with at least six potentially strategic companies that could open the door to future collaboration for distribution, investment, co-future development of future generations of the technology or even potential acquisition. Many of the spine surgeons and pain relief physicians visiting the booth stated that the DenerveX Design is very elegant, and represents a very new and creative approach in treating pain associated with the Facet Joint Syndrome. Their clear appreciation for our different approach in performing a new procedure by way of a posterior capsulectomy of the facet joint, compared to the less effective standard radio frequency ablation (Rhizotomy), gives us cause for continued cautious optimism going forward."

During EuroSpine 2016, Medovex also announced the official opening of the Company's European Distribution Center in Berlin.

The Center will serve as Medovex's European distribution service headquarters and function as the commercial hub for all European distributors, as well as other customer and technical support functions. The international operations center in Atlanta, GA (USA) will remain the Company's global operational headquarters.

Manfred Sablowski, Senior Vice President of Global Sales & Marketing, added, "The opening of the European distribution service center is an important milestone for Medovex and a key inflection point for our Company's strategy to grow our business in Europe, Middle Eastern and Africa regions. In the past months, we have additionally expanded our footprint to include all of Scandinavia and Israel. Our future goal is to increase our world-class EMEA distribution in other key countries. With the recent appointment of Juan Davila as Director Sales & Marketing for Latin America, having extensive experience in this market, we expect to continue to execute our go to market strategy."

The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power Generator, both designed to be less invasive with faster recovery time than current surgical treatment options. It consists of two procedures combined into one device and is expected to provide for a longer lasting treatment solution while offering potential savings to the health care system. DenerveX is not yet commercially available.

DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

 

 


Medovex Corporation Enters Into International Distribution Agreement With M.Fast Technologies LTD

Source:  Medovex Corp.

Leading Supplier of Innovative Spine Surgery Products to Distribute the DenerveX™ System Throughout Israel

Medovex Corp. (NASDAQ: MDVX) ("Medovex" or "Company"), a developer of medical technology products, today announced that the Company has entered into an international distribution agreement with M.Fast Technologies LTD, a supplier of innovative Spine surgery products. The agreement covers the distribution of its DenerveX™ System throughout Israel.

Dennis Moon, Medovex Executive Vice President, stated, "M.Fast Technologies LTD serves as a perfect call point fit for our mission to provide a successful distribution, sales and marketing foundation for our entry of the DenerveX System in the Middle East."

"With M.Fast Technologies LTD as a specialized distributor offering complex and innovative spine products throughout Israel, we are closing a gap while showing a professional presence in a major market," added Manfred Sablowski, Senior Vice President Sales & Marketing. "Today's news importantly enables Medovex to expand the use of the DenerveX System into the Middle East, where M.Fast Technologies is a well established successful distributor. We expect the agreement will help in our efforts to increase worldwide adoption of the DenerveX System."

Sablowski continued, "Our goal remains to continuously improve our international market presence by expanding our network of strong distributors with knowledgeable sales and support personnel, and in close proximity to our customers."

Medovex already has distribution agreements for the DenerveX System in Germany, Spain, UK, Denmark, Norway, Sweden, Finland in Europe and Asia Pacific, as well as in select other countries around the world.

The Company's patented DenerveX System, currently in final development and not yet commercially available, is designed to provide longer lasting relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.

The DenerveX System consists of the DenerveX device kit containing a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX System is designed to provide a minimally invasive treatment option which combines two actions into one device.

DenerveX is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com.


Medovex Corporation Expands Launch Plan With Latin American Management Hire

Source:  Medovex Corp.

Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that the Company has hired Mr. Juan Davila as Director Sales & Marketing for their DenerveX™ division of the business.

Mr. Davila, a Sales & Marketing leader with more than over 20 years of experience in the Latin-American Market, is recognized for his excellent record of business growth and market development of new products in the highly competitive medical devices industry in Latin America. Mr. Davila has a strong marketing and communication skills, in both Spanish and Portuguese.

Davila will be developing and implementing an overall corporate sales, marketing and strategy, directly engaging and managing all future Medovex Distributors throughout the Americas, and translating the company's business objectives into marketing strategies that drive future revenue. In addition, Mr. Davila will also provide services to help introduce the Medovex's DenerveX™ System to leading physicians and medical professionals in Latin America.

"Juan drives market awareness and qualified sales leads through a rare combination of medical technology savvy, customer, distributor focus and persuasive communication," said Manfred Sablowski, Medovex Senior Vice President Global Sales & Marketing. "His skill set spans all aspects of Sales & Marketing, and we are thrilled to be adding such a deep talent to the Medovex team."
Sablowski continues, "Juan Davila fits our mission to provide a world-wide distribution channel for our DenerveX System, while serving an important market segment in Latin America."

Prior to accepting this position, Davila established successful his own consulting firm with focus on the Latin American Healthcare Market and worked for Worldwide well known Medical Technology Companies like Valleylab (former Tyco/U.S Surgical/Pfizer) as General Manager Latin America which resulted in sales growth of 850% as well as Howmedica (former Pfizer).

The Company's patented DenerveX™ System is intended to treat Facet Joint Syndrome (FJS), a condition in which the joints in the back of the spine degenerate and subsequently cause pain. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to FJS pain.

The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power Generator, both designed to be less invasive with faster recovery time than current surgical treatment options. It consists of two procedures combined into one device and is expected to provide for a longer lasting treatment solution while offering potential savings to the health care system. DenerveX is not yet commercially available.

DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Medovex Corporation Adds 35 Year Orthopedic Industry Veteran Ron Lawson to Board of Directors

Source:  Medovex Corp.

Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, announced today that it has added orthopedic industry veteran Ron Lawson to its Board of Directors.

Ron Lawson's 35 plus years of experience in the orthopedic industry include the role as Senior Vice President of Worldwide Sales and Customer Service for Pfizer's Orthopedic Division, Howmedica (1996). In 1998, he became part of the Stryker Corporation with Stryker's acquisition of Howmedica. At Stryker, he served as Senior Vice President of Sales, Marketing and Product Development. Mr. Lawson also played a critical and insightful role in the successful integration of the two companies. In 2000, he was asked to lead the revitalization of Stryker's European business as President, EMEA. He shortly thereafter assumed the role of leadership for all of Stryker's International distribution businesses and was promoted to Group President, International in 2001.

In 2005, Stryker assigned global responsibility of their orthopedic division to Mr. Lawson making him Group President for International and Global Orthopedics. He then focused on strengthening the Stryker Orthopedic business worldwide. Ron retired from Stryker at the end of 2007.

Ron Lawson is currently a member of the Lawson Group where he provides strategic consulting services specializing in orthopedic medical technology. He previously served as Chairman of the Board of IMDS, Corporation. He also served as a member of the Health Care Advisory Board of Arsenal Capital Partners. He presently serves as a Director of Plasmology 4, Corporation as well as a Director of DJO Global, a Blackstone company.

Jarrett Gorlin, Medovex Corporation Chief Executive Officer, stated, "Mr. Lawson is well regarded as one of the key leaders aided in the development of the orthopedic industry. With the progress of our flagship DenerveX™ Device and other opportunities currently under review, his addition to our team is highly strategic. We look forward to working with Ron and leveraging his relationships throughout the world. I'd also like to say a special thank you to outgoing board member Thomas Hills for all of his invaluable support over the last couple years."

Ron Lawson added, "I am pleased to have the opportunity to serve on the Board of Medovex Corporation at a time I believe to be an inflection point for the Company. The company is now strategically positioned to offer great value to both surgeons and patients dealing with pain associated with the Facet Joint. I look forward to assisting management in identifying and vetting other potentially complementary additions to its portfolio of assets, as well as helping to further strengthen the Company's relationships with surgeon opinion leaders around the world."

The Company's patented DenerveX System is currently in the final development stages. It is designed to provide longer lasting relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and 31% of those affected are attributed to facet joint pain.

The DenerveX System consists of the DenerveX device kit, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined procedure is expected to provide a longer lasting solution and potential savings to the health care system.

DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Thursday, October 6, 2016

BFC Financial Corporation Declares Quarterly Cash Dividend

Source:  BFC Financial Corporation

BFC Financial Corporation ("BFC" or the "Company") (OTCQB: BFCF) (OTCQB: BFCFB) announced today that the Company's Board of Directors has declared a cash dividend payment of $0.005 per share on its Class A and Class B Common Stock, with a payment date of October 20, 2016, to all shareholders of record at the close of trading on September 23, 2016.
As previously announced on June 8, 2016, BFC has indicated its intention, subject to declaration by its Board, to pay regular quarterly dividends of $0.005 per share on its Class A and Class B Common Stock (an aggregate of $0.02 per share annually).

About BFC Financial Corporation:
BFC (OTCQB: BFCF) (OTCQB: BFCFB) is a holding company whose principal holdings include an 81% ownership interest in BBX Capital Corporation (NYSE: BBX) and its indirect ownership interest in Bluegreen Corporation. BFC owns a 54% equity interest in Woodbridge, the parent company of Bluegreen. BBX Capital owns the remaining 46% equity interest in Woodbridge. As of June 30, 2016, BFC had total consolidated assets of $1.4 billion, shareholders' equity attributable to BFC of $385.0 million, and total consolidated equity of $495.9 million. BFC's book value per share at June 30, 2016 was $4.61.

About Bluegreen Corporation:
Founded in 1966 and headquartered in Boca Raton, FL, Bluegreen is a sales, marketing and resort management company, focused on the vacation ownership industry and pursuing a capital-light business strategy. Bluegreen manages, markets and sells the Bluegreen Vacation Club, a flexible, points-based, deeded vacation ownership plan with more than 200,000 owners, 66 owned or managed resorts, and access to more than 4,500 resorts worldwide. Bluegreen also offers a portfolio of fee-based services, including resort management services, financial services, and sales and marketing services, to or on behalf of third parties.

For further information, please visit our family of companies:
BFC Financial Corporation: www.BFCFinancial.com
Bluegreen Corporation: www.BluegreenVacations.com
BBX Capital: www.BBXCapital.com

MOD Pizza Continues Growth in Key US Markets: Selects BBX Capital as New Franchisee for Florida

Source:  BFC Financial Corporation & BBX Capital

MOD Super Fast Pizza Holdings, LLC ("MOD Pizza" or "MOD"), a pioneer of fast-casual pizza, and BBX Capital Corporation ("BBX Capital") (NYSE: BBX) today announced that BBX Capital has joined its growing family of select franchisees. BBX Capital has created a new division with the goal of developing 50 or more MOD locations throughout central and southern Florida over the next seven years, including the major metropolitan markets of Miami, Fort Lauderdale, Palm Beach, Orlando and Tampa. With this agreement, MOD now has eight franchisees across the U.S., and commitments to open approximately 200 franchise locations in 12 states (California, Colorado, Missouri, Kansas, Michigan, Indiana, Ohio, Kentucky, Georgia, South Carolina, North Carolina, and Florida).

MOD currently has 152 locations across 18 states and the United Kingdom. Founded by entrepreneurs Scott and Ally Svenson, MOD was inspired by the couple's love of Italian street-style pizza, their desire for authentic, affordable and fast dining options for their busy family and the idea that a great company could be built around people. The Svensons bring their experience from building two highly successful concepts -- Seattle Coffee Company and Carluccio's. MOD's team of advisors and executives bring experience from iconic brands such as Starbucks, Apple, Disney, McDonald's, Dunkin Donuts, and T-Mobile.

BBX Capital has extensive financial, real estate, hospitality and restaurant experience. In addition to its real estate portfolio, the company currently owns Bluegreen Corporation, a vacation ownership company, Hoffman's Chocolates, a manufacturer of gourmet chocolates with retail locations throughout South Florida, and BBX Sweet Holdings, a portfolio of candy companies throughout the United States. BBX Capital previously owned BankAtlantic, one of the largest and oldest retail banks headquartered in the state of Florida.

"For MOD, the single most critical factor is ensuring that our franchisees echo our belief in the value of a strong and vibrant culture in our stores. We continue to have a simple goal in our franchising strategy -- to build deep relationships with a select and limited set of distinguished franchisees," said Scott Svenson, co-founder and CEO of MOD Pizza. "We are humbled that the team at BBX Capital has joined the MOD family and share our desire to build something new and very special. We know they have the local market expertise and experience to help us spread the MOD culture across their home State of Florida."

MOD, with a business strategy of predominantly building company-owned stores, complemented with a select group of culturally-aligned and highly experienced franchisees, is nearing the completion of its team of U.S. franchisees. "With the addition of one or two more U.S. franchisees, which would bring our total to 10, we will have solidified our network of operators who will help us grow across the country," said John Dikos, Vice President of Partnerships of MOD Pizza.

"MOD has established itself as a leader in the fast casual pizza category while offering consumers an authentic, affordable and fast dining experience," said Jarett Levan, President of BBX Capital. "MOD's strong brand, people-first culture, and best-in-class customer service has positioned MOD very well for continued growth, and we are very excited to be teaming with Scott and Ally, and the entire MOD family to bring the concept to Florida."

About MOD:MOD Pizza, a pioneer of the fast casual pizza segment, was founded in Seattle in 2008 by entrepreneurs Scott and Ally Svenson. MOD's individual artisan-style pizzas are made on demand, allowing customers to create their own pizzas and salads, using fresh-pressed dough, signature sauces and over 30 toppings, for one price. MOD was recently ranked as America's fastest growing chain restaurant by Technomic, earned a spot on the Inc. 5000 list as one of the fastest growing private companies in America in both 2015 and 2016 and was recognized by Fortune as one of the "20 Best Workplaces in Retail" for its progressive hiring practices and career growth opportunities. MOD has over 150 locations system-wide across 18 states and the United Kingdom. At the core of MOD is a purpose-led culture that is committed to being a force for good in communities throughout the U.S. and abroad, creating not only a cool place to eat, but an inspired place to work. For more information, please visit www.modpizza.com.

About BBX Capital Corporation:BBX Capital (NYSE: BBX) is involved in the acquisition, ownership and management of joint ventures and investments in real estate and real estate development projects, as well as acquisitions, investments and management of middle market operating businesses. In addition, BBX Capital and its controlling shareholder, BFC Financial Corporation, have a 46% and 54% respective ownership interest in Bluegreen Corporation. As a result of their ownership interests, BBX Capital and BFC together own 100% of Bluegreen. As of June 30, 2016, BBX Capital had total consolidated assets of $390.5 million, shareholders' equity attributable to BBX Capital of $ 335.5 million, and total consolidated equity of $337.4 million. BBX Capital's book value per share at June 30, 2016 was $20.47. For more information, please visit www.BBXCapital.com.

Bluegreen Vacations Celebrates the Grand Opening of the Club Lodges at Trillium, in Cashiers, North Carolina

Source:  BFC Financial Corporation & Bluegreen Corporation


Bluegreen Corporation, ("Bluegreen Vacations" or "Bluegreen"), today announced the official opening of The Club Lodges at Trillium and welcomed its first guests.

"The Club Lodges at Trillium is set within a private residential, lake and award-winning golf community in Cashiers, North Carolina. Bluegreen owners can, subject to applicable fees, enjoy the same activities and amenities as the community's residents. Playing golf at Trillium Links, one of the best courses in western North Carolina, enjoy a pool, indoor and outdoor tennis, croquet, two restaurants, a massage room, and a chapel," said David Pontius, Chief Strategy Officer. "However the 'Wow!' factor is the outdoors and the outdoor adventures at the Club Lodges at Trillium are abundant with breathtaking natural beauty, vast skies and virtually limitless outdoor recreational opportunities."
Nestled in the heart of Cashiers, North Carolina, The Club Lodges at Trillium offers Bluegreen Vacation Club owners another optimal vacation choice. This mountain chic resort is hidden in the heart of the Blue Ridge Mountains and on the pristine shores of the 6-mile Lake Glenville. The Club Lodges at Trillium debuted twenty-six, 2 and 3-bedroom suites, all with fresh, luxuriously appointed designs. Incorporated within Bluegreen Vacations' "fee-based services" business model, current plans for The Club Lodges at Trillium project once completed are anticipated to total 78 units delivered in three phases.

"At The Club Lodges at Trillium, Bluegreen Vacation Club owners can customize their mountain vacation experience by choosing either a two-bedroom villa or a 2,000-square-foot, three-bedroom Presidential suite. Once there, vacationers can enjoy cozy fireplaces and welcoming 'island' kitchens, all snuggled against a plateau lake and shoreline," commented Michael Hammond, General Manager. "If you're searching for a perfect vacation or a unique place for the family to get away from it all, the Club Lodges at Trillium is suited equally to vigorous recreation or tranquil R&R."
For further information about The Club Lodges at Trillium, please visit: https://www.bluegreenvacations.com/resorts/nc/club-lodges-at-trillium.

Bluegreen Corporation is wholly-owned by BFC Financial Corporation (OTCQB: BFCF) and BBX Capital (NYSE: BBX).

About Bluegreen Corporation:
Founded in 1966 and headquartered in Boca Raton, FL, Bluegreen is a sales, marketing and resort management company, focused on the vacation ownership industry and pursuing a capital-light business strategy. Bluegreen manages, markets and sells the Bluegreen Vacation Club, a flexible, points-based, deeded vacation ownership plan with more than 200,000 owners, 66 owned or managed resorts, and access to more than 4,500 resorts worldwide. Bluegreen also offers a portfolio of comprehensive, turnkey, fee-based services, including resort management services, financial services, and sales and marketing services, to or on behalf of third parties. For more information, visit www.BluegreenVacations.com.

For further information, please visit our family of companies:
Bluegreen Corporation: www.BluegreenVacations.com
BFC Financial Corporation: www.BFCFinancial.com
BBX Capital: www.BBXCapital.com

BFC Financial Corporation Reports Financial Results for the Second Quarter, 2016


Source:  BFC Financial Corporation



BFC Financial Corporation ("BFC" or the "Company") (OTCQB: BFCF) (OTCQB: BFCFB) reported financial results for the three and six month periods ended June 30, 2016.

Overview and Highlights:
BFC Selected Financial Data (Consolidated)Second Quarter 2016 Compared to Second Quarter 2015:
  • Total consolidated revenues of $193.0 million vs. $191.0 million
  • Net income attributable to BFC of $0.2 million vs. $84.3 million (1)
  • Diluted earnings per share of $0.0 vs. $0.97
  • "Free cash flow" (cash flow from operating activities less capital expenditures) was $23.4 million compared to $17.5 million
BFC Selected Financial Data (Consolidated)Six Months Ended June 30, 2016 Compared to Six Months Ended June 30, 2015:
  • Total consolidated revenues of $358.6 million vs. $341.0 million
  • Net income attributable to BFC of $5.7 million vs. $86.2 million (1)
  • Diluted earnings per share of $0.07 vs. $0.99
  • "Free cash flow" (cash flow from operating activities less capital expenditures) was $38.4 million compared to $10.0 million
(1) Net income attributable to BFC for the three and six month ended June 30, 2015 included a benefit for income taxes of $92.3 million due to the release of a portion of BFC's valuation allowance on its net deferred tax asset.
As of June 30, 2016, BFC had total consolidated assets of $1.4 billion, shareholders' equity attributable to BFC of $385.0 million, and total consolidated equity of $495.9 million. At June 30, 2016, BFC's book value per share was $4.61 compared to $4.08 at June 30, 2015.

"BFC and BBX Capital Corporation ("BBX Capital" or "BBX") (NYSE: BBX) recently announced that they entered into a definitive merger agreement between the companies. As discussed in more detail below, BFC has held a meaningful stake in BBX since 1987, and if the proposed merger is consummated, BBX will be a wholly owned subsidiary of BFC. The proposed merger of BFC and BBX is anticipated to simplify our corporate structure and intended to consolidate and streamline the combined companies. Also discussed in more detail below, BFC announced that its Board declared a quarterly cash dividend on BFC's Common Stock during the quarter and, subject to declaration by the Board each quarter, anticipates paying regular quarterly dividends in the future," commented Jarett S. Levan, Acting Chairman and Chief Executive Officer of BFC Financial.

On July 27, 2016, BFC and BBX Capital entered into a definitive merger agreement between the companies. Under the terms of the merger agreement, which was unanimously approved by a special committee comprised of BBX's independent directors as well as the boards of directors of both companies, BBX's shareholders other than BFC will be entitled to receive, at their election, 5.4 shares of BFC's Class A Common Stock or $20.00 in cash for each share of BBX's Class A Common Stock held by them. BBX Capital's shareholders will have the right to elect to make different elections with respect to different shares held by them so they may elect to receive all cash, all stock, or a combination of cash and stock in exchange for their shares. If the merger is consummated, BBX will be a wholly owned subsidiary of BFC.

On June 8, 2016, the Company announced that its Board of Directors had declared a cash dividend payment of $0.005 per share on its Class A and Class B Common Stock. The dividend was paid on July 20, 2016, to all shareholders of record at the close of trading on June 20, 2016. BFC has indicated its intention to, subject to declaration by its Board, pay regular quarterly dividends of $0.005 per share on its Class A and Class B Common Stock (an aggregate of $0.02 per share annually).

The results of operations and financial condition of the companies in which BFC holds a controlling financial interest, including BBX Capital Corporation and Woodbridge Holdings, LLC ("Woodbridge"), the parent company of Bluegreen, are consolidated in BFC's financial statements. BFC currently holds an approximate 81% ownership interest in BBX Capital. Woodbridge is owned 54% by BFC and 46% by BBX Capital. Woodbridge's principal asset is its 100% ownership interest in Bluegreen.

The following selected information relates to the operating activities of Bluegreen and BBX Capital. See the supplemental tables below for the consolidating statements of operations for the three and six month periods ended June 30, 2016 and 2015.
Bluegreen Corporation
Bluegreen is a sales, marketing, and management company focused on the vacation ownership industry. Bluegreen markets, sells and manages vacation ownership interests ("VOIs)" in resorts, which are generally located in popular, high-volume, "drive-to" vacation destinations. The resorts in which Bluegreen markets, sells or manages VOIs were either developed or acquired by Bluegreen, or were developed and are owned by third parties. Bluegreen earns fees for providing sales and marketing services to these third party developers. Bluegreen also earns fees by providing management services to the Bluegreen Vacation Club and property owners associations ("POAs"), mortgage servicing, VOI title services, reservation services, and construction design and development services. In addition, Bluegreen provides financing to individual purchasers of VOIs.
During the three month period ended June 30, 2016, Bluegreen paid cash dividends of $15.0 million to Woodbridge, Bluegreen's parent company, and Woodbridge in turn paid $7.6 million of cash dividends to BFC and $6.5 million of cash dividends to BBX Capital. During the six month period ended June 30, 2016, Bluegreen paid cash dividends of $25.0 million to Woodbridge, and Woodbridge in turn paid $12.6 million of cash dividends to BFC and $10.7 million of cash dividends to BBX Capital.
Bluegreen Selected Financial DataSecond Quarter 2016 Compared to Second Quarter 2015:
  • System-wide sales of VOIs, net of equity trade allowances (2), were $159.7 million vs. $139.9 million. Included in system-wide sales are sales of VOIs made as part of Bluegreen's "capital-light" business strategy(1), which were $125.8 million vs. $111.0 million, gross of equity trade allowances(2):
    • Sales of third party VOIs on a commission basis were $77.6 million vs. $70.9 million and generated sales and marketing commissions of $54.2 million vs. $48.0 million
    • Sales of secondary market VOIs were $26.8 million vs. $24.2 million
    • Sales of just-in-time VOIs were $21.4 million vs. $15.9 million
  • Average sales price per transaction was $13,293 versus $12,325
  • Sales volume per guest averaged $2,239 vs. $2,328
  • Tours increased 19% compared to prior year quarter
  • Other fee-based services revenue was $26.1 million vs. $24.9 million
  • Net income attributable to Bluegreen was $14.0 million vs. $17.9 million. Excluding special bonuses totaling $10.0 million paid to certain employees, Bluegreen's net income would have been $20.1 million for the three months ended June 30, 2016.
  • EBITDA was $25.1 million vs. $32.2 million (3). Excluding the special bonuses discussed above, EBITDA would have been $35.1 million for the three months ended June 30, 2016.
  • "Free cash flow" (cash flow from operating activities less capital expenditures) was $28.7 million compared to $18.2 million
Bluegreen Selected Financial DataSix Months Ended June 30, 2016 Compared to Six Months Ended June 30, 2015:
  • System-wide sales of VOIs, net of equity trade allowances (2), were $286.7 million vs. $249.1 million. Included in system-wide sales are sales of VOIs made under Bluegreen's "capital-light" business strategy(1), which were $224.4 million vs. $189.4 million, gross of equity trade allowances(2):
    • Sales of third party VOIs on a commission basis were $137.7 million vs. $119.9 million and generated sales and marketing commissions of $94.3 million vs. $80.6 million
    • Sales of secondary market VOIs were $61.0 million vs. $46.8 million
    • Sales of just-in-time VOIs were $25.7 million vs. $22.7 million
  • Average sales price per transaction was $13,265 vs. $12,390
  • Sales volume per guest averaged $2,268 vs. $2,355
  • Tours increased 21% compared to prior year period
  • Other fee-based services revenue was $51.6 million vs. $48.7 million
  • Net income attributable to Bluegreen was $31.5 million vs. $33.9 million. Excluding special bonuses totaling $10.0 million paid to certain employees, Bluegreen's net income would have been $37.6 million for the six months ended June 30, 2016.
  • EBITDA was $55.5 million vs. $63.0 million (3). Excluding the special bonuses discussed above, EBITDA would have been $65.5 million for the six months ended June 30, 2016.
  • "Free cash flow" (cash flow from operating activities less capital expenditures) was $60.0 million compared to $30.1 million
(1) Bluegreen's sales of VOIs under its capital-light business strategy include sales of VOIs under fee-based sales and marketing arrangements, just-in-time inventory acquisition arrangements, and secondary market arrangements. Under "just-in-time" arrangements, Bluegreen enters into agreements with third party developers that allow Bluegreen to buy VOI inventory from time to time in close proximity to the timing of when Bluegreen intends to sell such VOIs. Bluegreen also acquires VOI inventory from resorts' POA and other third parties close to the time Bluegreen intends to sell such VOIs. Such VOIs are typically obtained by the POAs through foreclosure in connection with maintenance fee defaults, and are generally acquired by Bluegreen at a significant discount. Bluegreen refers to sales of inventory acquired through these arrangements as "Secondary Market Sales."
(2) Equity trade allowances are amounts granted to customers upon trading in their existing VOIs in connection with the purchase of additional VOIs.
(3) See the supplemental tables included in this release for a reconciliation of EBITDA to net income.
   
Bluegreen Summary for the Three and Six Months Ended June 30, 2016
System-wide sales of VOIs were $159.7 million and $286.7 million during the three and six months ended June 30, 2016, respectively, and $139.9 million and $249.1 million during the three and six months ended June 30, 2015, respectively. The growth in system-wide sales during the three and six months ended June 30, 2016 is primarily attributable to an increase of 19% and 21%, respectively, in the number of total prospect tours, which included an increase of 27% and 29%, respectively, in the number of new prospect tours, and an increase of 8% and 7%, respectively, in the average sales price per transaction. These increases were partially offset by a decrease of 11% and 10%, respectively, in the sale to tour conversion ratio for total prospects and a decrease of 11% and 9%, respectively, in the sale to tour conversion ratio for new prospects.

Fee-based sales commission revenue was $54.2 million and $48.0 million during the three months ended June 30, 2016 and 2015, respectively, and $94.3 million and $80.6 million during the six months ended June 30, 2016 and 2015, respectively. The increase in the sales of third-party developer inventory during the 2016 periods were due primarily to the factors described above related to the increase in system-wide sales of VOIs. In addition, Bluegreen earned an average sales and marketing commission of 70% and 69% during the three and six months ended June 30, 2016, respectively, as compared to 68% and 67% during the three and six months ended June 30, 2015, respectively. The increase in the second quarter of 2016 included an incentive commission of $1.7 million earned as a result of the achievement of certain sales thresholds pursuant to the terms and conditions of the applicable contractual arrangement.

Other fee-based services revenue increased 4% to $26.1 million for the three months ended June 30, 2016 and 6% to $51.6 million for the six months ended June 30, 2016. Fee-based management services revenues increased during the 2016 periods compared to the 2015 periods primarily as a result of cumulative increases in the number of owners in the Bluegreen Vacation Club.
Net interest spread was $13.9 million and $12.6 million during the three months ended June 30, 2016 and 2015, respectively, and $28.2 million and $22.0 million during the six months ended June 30, 2016 and 2015, respectively. The increase in net interest spread during the three and six months ended June 30, 2016 is primarily due to additional interest income of $0.4 million and $2.4 million recognized by Bluegreen during the three and six months ended June 30, 2016, respectively, related to an $80.0 million loan made to BFC during April 2015.

Bluegreen generated "free cash flow" (cash flow from operating activities less capital expenditures) of $60.0 million during the six months ended June 30, 2016 compared to $30.1 million during the six months ended June 30, 2015. The increase for the 2016 period is primarily due to decreased spending on the acquisition and development of inventory. During the first six months of 2016, Bluegreen paid $5.2 million for development expenditures primarily related to the Bluegreen/Big Cedar Vacations Joint Venture, as compared to $19.7 million in the 2015 period. Additionally, Bluegreen paid $2.7 million for Just-in-Time inventory purchases during the first six months of 2016 as compared to $9.9 million during the same 2015 period. This increase was partially offset by the impact of a decrease in cash realized within 30 days of sale to 41% during the six months ended June 30, 2016 from 47% during the six months ended June 30, 2015.
BBX Capital Corporation
BBX Capital is involved in the acquisition, ownership and management of joint ventures and investments in real estate and real estate development projects, as well as investments in and management of middle market operating businesses, in each case directly or indirectly through subsidiaries or joint ventures.
BBX Selected Financial DataSecond Quarter 2016 Compared to Second Quarter 2015:
  • Total consolidated revenues of $24.0 million vs. $38.6 million
  • Net loss attributable to BBX Capital of ($2.2) million vs. net income of $4.1 million
  • Equity in income of Woodbridge Holdings, LLC of $5.1 million vs. loss of ($10.2) million
BBX Selected Financial DataSix Months Ended June 30, 2016 Compared to Six Months Ended June 30, 2015:
  • Total consolidated revenues of $47.7 million vs. $60.3 million
  • Net loss attributable to BBX Capital of ($2.5) million vs. net income of $5.2 million
  • Diluted loss per share of ($0.15) vs. diluted earnings per share of $0.31
  • Equity in income of Woodbridge Holdings, LLC of $11.8 million vs. net loss of ($4.4) million
As of June 30, 2016, BBX Capital had total consolidated assets of $390.5 million, shareholders' equity attributable to BBX Capital of $335.5 million, and total consolidated equity of $337.4 million. At June 30, 2016, BBX Capital's book value per share was $20.47 vs. $19.63 at June 30, 2015.
For more detailed information regarding BBX Capital and its financial results, business, operations and risks, please see BBX Capital's financial results press release for the quarter ended June 30, 2016, BBX Capital's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, and BBX Capital's Annual Report on Form 10-K for the year ended December 31, 2015, which are available to view on the SEC's website, www.sec.gov, and on BBX Capital's website, www.BBXCapital.com.
For more complete and detailed information regarding BFC and its financial results, business, operations and risks, and Bluegreen Corporation, please see BFC's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, and BFC's Annual Report on Form 10-K for the year ended December 31, 2015, which are available on the SEC's website, www.sec.gov, and on BFC's website, www.BFCFinancial.com.

About BFC Financial Corporation:BFC (OTCQB: BFCF) (OTCQB: BFCFB) is a holding company whose principal holdings include an 81% ownership interest in BBX Capital Corporation (NYSE: BBX) and its indirect ownership interest in Bluegreen Corporation. BFC owns a 54% equity interest in Woodbridge, the parent company of Bluegreen. BBX Capital owns the remaining 46% equity interest in Woodbridge. As of June 30, 2016, BFC had total consolidated assets of $1.4 billion, shareholders' equity attributable to BFC of $385.0 million, and total consolidated equity of $495.9 million. BFC's book value per share at June 30, 2016 was $4.61.

About Bluegreen Corporation:Founded in 1966 and headquartered in Boca Raton, FL, Bluegreen is a sales, marketing and resort management company, focused on the vacation ownership industry and pursuing a capital-light business strategy. Bluegreen manages, markets and sells the Bluegreen Vacation Club, a flexible, points-based, deeded vacation ownership plan with more than 200,000 owners, 66 owned or managed resorts, and access to more than 4,500 resorts worldwide. Bluegreen also offers a portfolio of comprehensive, turnkey, fee-based services, including resort management services, financial services, and sales and marketing services, to or on behalf of third parties.

About BBX Capital Corporation:BBX Capital (NYSE: BBX) is involved in the acquisition, ownership and management of joint ventures and investments in real estate and real estate development projects, as well as acquisitions, investments and management of middle market operating businesses. In addition, BBX Capital and its controlling shareholder, BFC Financial Corporation, have a 46% and 54% respective ownership interest in Bluegreen Corporation. As a result of their ownership interests, BBX Capital and BFC together own 100% of Bluegreen. As of June 30, 2016, BBX Capital had total consolidated assets of $390.5 million, shareholders' equity attributable to BBX Capital of $335.5 million, and total consolidated equity of $337.4 million. BBX Capital's book value per share at June 30, 2016 was $20.47.

For further information, please visit our family of companies:BFC Financial Corporation: www.BFCFinancial.comBluegreen Corporation: www.BluegreenVacations.comBBX Capital: www.BBXCapital.com

Additional Information and Where to Find it:BFC will file with the SEC a Registration Statement on Form S-4 that will include a prospectus of BFC and a proxy statement of BBX Capital relating to the proposed merger between the companies discussed in this press release. The proxy statement/prospectus will be sent to the shareholders of BBX. Investors and shareholders will be able to obtain a copy of the proxy statement/prospectus and other documents filed with the SEC containing information about BFC and BBX Capital free-of-charge from the SEC's website at www.sec.gov. Copies of documents filed with the SEC by BFC will be made available free-of-charge on BFC's website at www.bfcfinancial.com, under the "Investor Relations" tab, or by written request to BFC Financial Corporation, 401 East Las Olas Boulevard, Suite 800, Fort Lauderdale, Florida 33301, Attention: Investor Relations, or by phone at 954-940-4900. Copies of documents filed with the SEC by BBX Capital will be made available free-of-charge on BBX Capital's website at www.bbxcapital.com, under the "Investor Relations" tab, or by written request to BBX Capital Corporation, 401 East Las Olas Boulevard, Suite 800, Fort Lauderdale, Florida 33301, Attention: Investor Relations, or by phone at 954-940-4000. Investors and shareholders are advised to read the proxy statement/prospectus when it is available because it will contain important information.

BFC, BBX and certain of their respective directors and executive officers may, under the rules of the SEC, be deemed to be "participants" in the solicitation of proxies from BBX's shareholders in connection with the proposed merger. Information about the directors and executive officers of BFC is set forth in BFC's Proxy Statement on Schedule 14A for its 2016 Annual Meeting of Shareholders, which was filed with the SEC on April 28, 2016. Information about the directors and executive officers of BBX Capital is set forth in BBX Capital's Proxy Statement on Schedule 14A for its 2016 Annual Meeting of Shareholders, which was filed with the SEC on April 25, 2016. These documents can be obtained free-of-charge from the sources indicated above. Information concerning the interests of the persons who may be considered "participants" in the solicitation will be set forth in the proxy statement/prospectus relating to the merger when it becomes available.

BFC Financial Corporation and BBX Capital Corporation Announce Definitive Agreement to Merge

Source:  BFC Financial Corporation

BFC Financial Corporation ("BFC Financial" or "BFC") (OTCQB: BFCF) (OTCQB: BFCFB) and BBX Capital Corporation ("BBX Capital" or "BBX") (NYSE: BBX) announced today that they have entered into a definitive merger agreement between the companies.

Under the terms of the merger agreement, which was unanimously approved by a special committee comprised of BBX's independent directors as well as the boards of directors of both companies, BBX's shareholders other than BFC will be entitled to receive, at their election, 5.4 shares of BFC's Class A Common Stock or $20.00 in cash for each share of BBX's Class A Common Stock held by them. BBX Capital's shareholders will have the right to elect to receive all cash, all stock, or a combination of cash and stock in exchange for their shares. BFC currently owns approximately 81% of BBX's Class A Common Stock and 100% of its Class B Common Stock. If the merger is consummated, BBX will be a wholly owned subsidiary of BFC.

Consummation of the merger is subject to certain conditions, including approval of the merger agreement by BBX's shareholders generally and by the holders of a majority of the shares of BBX's Class A Common Stock voted on the merger agreement other than those voted by BFC and its affiliates. Shareholders of BBX who do not vote in favor of the merger and who comply with the other requirements of Florida law with respect to appraisal rights will be entitled to appraisal rights in connection with the merger. However, unless waived by BFC, the merger is conditioned on holders of not more than 150,000 shares of BBX's Class A Common Stock exercising appraisal rights. The merger is not subject to a financing condition.

The largest asset held by both companies is their respective interests in Bluegreen Corporation, a hospitality, sales and marketing company. BFC owns 54% and BBX owns 46% of Woodbridge Holdings, LLC, the parent company of Bluegreen. Based on BFC's 54% ownership interest in Bluegreen and BFC's 81% ownership interest in BBX, BFC effectively has a 91% direct and indirect ownership interest in Bluegreen.

It is currently anticipated that the merger will be consummated promptly after all conditions to closing the merger are satisfied or, to the extent permitted under applicable law or the merger agreement, waived. The boards of each company took steps to exempt the transaction from the operation of such company's shareholder rights plan.

"The proposed merger of BFC and BBX is being undertaken in order to simplify our corporate structure. BFC has held a meaningful stake in BBX since 1987 and this merger is intended to consolidate and streamline the combined companies," commented Jarett S. Levan, Acting Chairman and Chief Executive Officer of both BFC and BBX.

Additional Information and Where to Find it:
BFC will file with the SEC a Registration Statement on Form S-4 that will include a prospectus of BFC and a proxy statement of BBX Capital. The proxy statement/prospectus will be sent to the shareholders of BBX. Investors and shareholders will be able to obtain a copy of the proxy statement/prospectus and other documents filed with the SEC containing information about BFC and BBX Capital free-of-charge from the SEC's website at www.sec.gov. Copies of documents filed with the SEC by BFC will be made available free-of-charge on BFC's website at www.bfcfinancial.com, under the "Investor Relations" tab, or by written request to BFC Financial Corporation, 401 East Las Olas Boulevard, Suite 800, Fort Lauderdale, Florida 33301, Attention: Investor Relations, or by phone at 954-940-4900. Copies of documents filed with the SEC by BBX Capital will be made available free-of-charge on BBX Capital's website at www.bbxcapital.com, under the "Investor Relations" tab, or by written request to BBX Capital Corporation, 401 East Las Olas Boulevard, Suite 800, Fort Lauderdale, Florida 33301, Attention: Investor Relations, or by phone at 954-940-4000.

Investors and shareholders are advised to read the proxy statement/prospectus when it is available because it will contain important information.

BFC, BBX and certain of their respective directors and executive officers may, under the rules of the SEC, be deemed to be "participants" in the solicitation of proxies from BBX's shareholders in connection with the merger. Information about the directors and executive officers of BFC is set forth in BFC's Proxy Statement on Schedule 14A for its 2016 Annual Meeting of Shareholders, which was filed with the SEC on April 28, 2016. Information about the directors and executive officers of BBX Capital is set forth in BBX Capital's Proxy Statement on Schedule 14A for its 2016 Annual Meeting of Shareholders, which was filed with the SEC on April 25, 2016. These documents can be obtained free-of-charge from the sources indicated above. Information concerning the interests of the persons who may be considered "participants" in the solicitation will be set forth in the proxy statement/prospectus relating to the merger when it becomes available.

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval in any jurisdiction where such an offer or solicitation is unlawful. Any such offer will be made only by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act").

About BFC Financial Corporation:
BFC (OTCQB: BFCF) (OTCQB: BFCFB) is a holding company whose principal holdings include an 81% ownership interest in BBX Capital Corporation (NYSE: BBX) and its indirect ownership interest in Bluegreen Corporation. BFC owns a 54% equity interest in Woodbridge, the parent company of Bluegreen. BBX Capital owns the remaining 46% equity interest in Woodbridge. As of March 31, 2016, BFC had total consolidated assets of $1.4 billion, shareholders' equity attributable to BFC of $385.2 million, and total consolidated equity of $493.4 million.

About BBX Capital Corporation:
BBX Capital (NYSE: BBX) is involved in the acquisition, ownership and management of joint ventures and investments in real estate and real estate development projects, as well as acquisitions, investments and management of middle market operating businesses. In addition, BBX Capital and its controlling shareholder, BFC Financial Corporation, have a 46% and 54% respective ownership interest in Bluegreen Corporation. As a result of their ownership interests, BBX Capital and BFC together own 100% of Bluegreen. As of March 31, 2016, BBX Capital had total consolidated assets of $392.1 million, shareholders' equity attributable to BBX Capital of $336.0 million, and total consolidated equity of $337.3 million.

About Bluegreen Corporation:
Founded in 1966 and headquartered in Boca Raton, FL, Bluegreen is a sales, marketing and resort management company, focused on the vacation ownership industry and pursuing a capital-light business strategy. Bluegreen manages, markets and sells the Bluegreen Vacation Club, a flexible, points-based, deeded vacation ownership plan with more than 199,000 owners, 66 owned or managed resorts, and access to more than 4,500 resorts worldwide. Bluegreen also offers a portfolio of comprehensive, turnkey, fee-based services, including resort management services, financial services, and sales and marketing services, to or on behalf of third parties.

For further information, please visit:
BFC Financial Corporation: www.BFCFinancial.com
BBX Capital: www.BBXCapital.com
Bluegreen Corporation: www.BluegreenVacations.com

BFC Financial Proudly Announces Bluegreen's Milestone: Bluegreen Vacations Commences Its 50th Golden Anniversary Celebrations

Source:  BFC Financial Corporation

Celebrating 50 Years of Families Creating Smiles, Memories and Time Together

BFC Financial Corporation ("BFC" or the "Company") (OTCQB: BFCF) (OTCQB: BFCFB) and Bluegreen Corporation ("Bluegreen Vacations" or "Bluegreen") today announced that Bluegreen is celebrating its 50th Golden Anniversary.

"This year marks the 50th Golden Anniversary of Bluegreen Vacations, an accomplishment we take great pride in. From one resort in the Smoky Mountains, the Bluegreen Vacation Club® has grown to 66 resorts, access to more than 4,500 resorts worldwide, and more than 199,000 owners enjoying the choice, flexibility and value that only Bluegreen can provide," commented Jarett S. Levan, Acting Chairman and Chief Executive Officer of BFC Financial and BBX Capital. "Bluegreen's 'Share Happiness' philosophy has helped create countless memories for vacationers over the decades, and we'd like to thank all of the owners, guests, business partners, and nearly 6,000 associates throughout North America who made this milestone possible."

Bluegreen's 50th Anniversary Milestones:
  • Bluegreen Vacations traces its lineage to a small community development company founded in the Berkshires of Massachusetts in 1966. It later relocated its headquarters to Stamford, Vermont, and in 1991 moved its headquarters to Boca Raton, Florida. Bluegreen developed its first vacation ownership resort in the Smoky Mountains in 1994. Other resorts soon followed.
  • In 1997, Bluegreen acquired RDI Group, a privately held vacation ownership developer and operator of a points-based vacation club with resorts in Florida and Wisconsin, plus management contracts with resorts across the Southeast. The RDI Group acquisition positioned Bluegreen as one of the largest property managers of vacation ownership resorts in the United States, and the Bluegreen Vacation Club® was born!
  • In 2000, Bluegreen established one of the vacation ownership industry's first national retail alliances by entering an exclusive marketing agreement with Bass Pro Shops® Inc. This agreement allows Bluegreen Vacations to market vacation opportunities at Bass Pro national retail locations, in Bass Pro catalogs and on the Bass Pro Shops® website. Bluegreen also entered into a joint venture agreement with Big Cedar, LLC, an affiliate of Bass Pro Shops®, to develop, market and sell the Bluegreen Wilderness Club at Big Cedar®, which became a trio of Bluegreen Vacation Club resorts located near the majestic Table Rock Lake in Missouri.
  • In 2006, Bluegreen announced the development of a resort in one of the world's premier vacation destinations, Las Vegas. In 2008, the first Presidential Suite was built at Daytona SeaBreeze, signaling a new wave of diverse accommodation options. In 2009, Bluegreen launched its Fee-Based Service business, establishing a platform to provide services such as sales and marketing, resort management and loan servicing, amongst others, to third party developers. Bluegreen continues to use this business model as a "capital-light" means of adding exciting new destinations to the Bluegreen Vacation Club such as New York (NY), Big Bear Lake (CA) and St. Pete Beach (FL).
  • And, in 2013, Bluegreen Vacations was named the Official Vacation Ownership provider of Choice Hotels®, one of the largest and most successful lodging companies in the world.
  • For more detailed information relating to the Bluegreen story, please visit https://www.bluegreenvacations.com/about/history/
"Bluegreen's pursuit of its capital-light business strategy has resulted in significant growth and has made Bluegreen one of the leading leisure, hospitality, and vacation ownership companies in the market sector. Its platform supports a portfolio of revenues associated with: the traditional vacation ownership business, a growing fee-based services business, resort management and the finance business. For the year ended December 31, 2015, Bluegreen reported system-wide sales of Vacation Ownership Interests of $552.7 million, other fee-based services revenue of $97.5 million, and net income of $82.0 million," commented Tony Puleo, Chief Financial Officer and Treasurer of Bluegreen Vacations.

"July is the start of the height of vacation season and we think an ideal time for families to 'share happiness,' creating smiles, memories and time together, and celebrating Bluegreen's 50th anniversary. Happy 50th Bluegreen!" added Levan.

For further information, please visit Bluegreen Vacations at www.BluegreenVacations.com

About Bluegreen Corporation:
Founded in 1966 and headquartered in Boca Raton, FL, Bluegreen is a sales, marketing and resort management company, focused on the vacation ownership industry and pursuing a capital-light business strategy. Bluegreen manages, markets and sells the Bluegreen Vacation Club, a flexible, points-based, deeded vacation ownership plan with more than 199,000 owners, 66 owned or managed resorts, and access to more than 4,500 resorts worldwide. Bluegreen also offers a portfolio of comprehensive, turnkey, fee-based services, including resort management services, financial services, and sales and marketing services, to or on behalf of third parties.

About BFC Financial Corporation:
BFC (OTCQB: BFCF) (OTCQB: BFCFB) is a holding company whose principal holdings include an 81% ownership interest in BBX Capital Corporation (NYSE: BBX) and its indirect ownership interest in Bluegreen Corporation. BFC owns a 54% equity interest in Woodbridge, the parent company of Bluegreen. BBX Capital owns the remaining 46% equity interest in Woodbridge. As a result of their ownership interests, BFC and BBX own 100% of Bluegreen. As of March 31, 2016, BFC had total consolidated assets of $1.4 billion, shareholders' equity attributable to BFC of $385.2 million, and total consolidated equity of $493.4 million. BFC's book value per share at March 31, 2016 was $4.56.